Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (15723)	2/27/2006 9:09:33 PM
From: Raj Ramaswamy	Read Replies (2) \| Respond to of 23958

You must be kidding...biotech with blockbuster drugs on fastrack always have expenses (trials, R&D etc). So forget the 'earnings'..there is none..what would you expect ? ! See VRTX...it was at 17+ range not too long ago..their just one blockbuster drug to treat Hep-c has lifted the stock to 45+ today.. I see strong parallel between VRTX and NUVO. Secondary not too long ago at 16+..what does it say to you ? It is not momo traders who bought at this price :-)